Straightforward guidance about neurological symptoms, conditions, diagnostic testing, and treatment—written to help patients and families feel better prepared for what comes next.
The FDA approved Zepbound, the first medication for obstructive sleep apnea. Here’s who it helps, whether it replaces CPAP, and how to get evaluated in Western Maryland.
Vertex’s non-opioid drug suzetrigine entered Phase 3 trials for diabetic nerve pain. Learn what’s investigational, why it matters, and when an EMG helps.
The FDA cleared Axon Therapy, a noninvasive magnetic nerve stimulation device for painful diabetic neuropathy. Learn how it works and who it may help.
BTK inhibitors are a new approach for progressive MS. Roche’s fenebrutinib hit its Phase 3 goal while Sanofi’s tolebrutinib got an FDA CRL. Here is the honest picture.
The FDA approved the first complex generic of Copaxone (glatiramer acetate) for relapsing MS in January 2026. Here is what it means for cost, insurance, and access.
Epilepsy care is shifting toward precision medicine and gene-targeted therapies. Learn what this means for patients and families, with examples now in trials.
If one of these articles sounds familiar, our team can help you move from symptoms and questions to testing, diagnosis, and follow-up treatment.
11110 Medical Campus Rd Unit 151, Hagerstown, MD 21742
924 Seton Dr Suite C, Cumberland, MD 21502
(301) 797-7600
Secure online messaging, records, and follow-up access for existing patients.